Joshua L Chan1, Justin G Miller1, Yifu Zhou1, Pamela G Robey2, David F Stroncek3, Andrew E Arai4, Vandana Sachdev5, Keith A Horvath6. 1. Cardiothoracic Surgery Research Program, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. 2. NIH Bone Marrow Stromal Cell Transplantation Center, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland. 3. Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland. 4. Advanced Cardiovascular Imaging Group, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. 5. Echocardiography Laboratory, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. 6. Cardiothoracic Surgery Research Program, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: khorvath@aamc.org.
Abstract
BACKGROUND: Bone marrow stromal or stem cells (BMSCs) remain a promising potential therapy for ischemic cardiomyopathy. The primary objective of this study was to evaluate the safety and feasibility of direct intramyocardial injection of autologous BMSCs in patients undergoing transmyocardial revascularization (TMR) or coronary artery bypass graft surgery (CABG). METHODS: A phase I trial was conducted on adult patients who had ischemic heart disease with depressed left ventricular ejection fraction and who were scheduled to undergo TMR or CABG. Autologous BMSCs were expanded for 3 weeks before the scheduled surgery. After completion of surgical revascularization, BMSCs were directly injected into ischemic myocardium. Safety and feasibility of therapy were assessed. Cardiac functional status and changes in quality of life were evaluated at 1 year. RESULTS: A total of 14 patients underwent simultaneous BMSC and surgical revascularization therapy (TMR+BMSCs = 10; CABG+BMSCs = 4). BMSCs were successfully expanded, and no significant complications occurred as a result of the procedure. Regional contractility in the cell-treated areas demonstrated improvement at 12 months compared with baseline (TMR+BMSCs Δ strain: -4.6% ± 2.1%; P = .02; CABG+MSCs Δ strain: -4.2% ± 6.0%; P = .30). Quality of life was enhanced, with substantial reduction in angina scores at 1 year after treatment (TMR+BMSCs: 1.3 ± 1.2; CABG+MSCs: 1.0 ± 1.4). CONCLUSIONS: In this phase I trial, direct intramyocardial injection of autologous BMSCs in conjunction with TMR or CABG was technically feasible and could be performed safely. Preliminary results demonstrate improved cardiac function and quality of life in patients at 1 year after treatment.
BACKGROUND: Bone marrow stromal or stem cells (BMSCs) remain a promising potential therapy for ischemic cardiomyopathy. The primary objective of this study was to evaluate the safety and feasibility of direct intramyocardial injection of autologous BMSCs in patients undergoing transmyocardial revascularization (TMR) or coronary artery bypass graft surgery (CABG). METHODS: A phase I trial was conducted on adult patients who had ischemic heart disease with depressed left ventricular ejection fraction and who were scheduled to undergo TMR or CABG. Autologous BMSCs were expanded for 3 weeks before the scheduled surgery. After completion of surgical revascularization, BMSCs were directly injected into ischemic myocardium. Safety and feasibility of therapy were assessed. Cardiac functional status and changes in quality of life were evaluated at 1 year. RESULTS: A total of 14 patients underwent simultaneous BMSC and surgical revascularization therapy (TMR+BMSCs = 10; CABG+BMSCs = 4). BMSCs were successfully expanded, and no significant complications occurred as a result of the procedure. Regional contractility in the cell-treated areas demonstrated improvement at 12 months compared with baseline (TMR+BMSCs Δ strain: -4.6% ± 2.1%; P = .02; CABG+MSCs Δ strain: -4.2% ± 6.0%; P = .30). Quality of life was enhanced, with substantial reduction in angina scores at 1 year after treatment (TMR+BMSCs: 1.3 ± 1.2; CABG+MSCs: 1.0 ± 1.4). CONCLUSIONS: In this phase I trial, direct intramyocardial injection of autologous BMSCs in conjunction with TMR or CABG was technically feasible and could be performed safely. Preliminary results demonstrate improved cardiac function and quality of life in patients at 1 year after treatment.
Authors: Luciano C Amado; Anastasios P Saliaris; Karl H Schuleri; Marcus St John; Jin-Sheng Xie; Stephen Cattaneo; Daniel J Durand; Torin Fitton; Jin Qiang Kuang; Garrick Stewart; Stephanie Lehrke; William W Baumgartner; Bradley J Martin; Alan W Heldman; Joshua M Hare Journal: Proc Natl Acad Sci U S A Date: 2005-08-01 Impact factor: 11.205
Authors: Vasileios Karantalis; Darcy L DiFede; Gary Gerstenblith; Si Pham; James Symes; Juan Pablo Zambrano; Joel Fishman; Pradip Pattany; Ian McNiece; John Conte; Steven Schulman; Katherine Wu; Ashish Shah; Elayne Breton; Janice Davis-Sproul; Richard Schwarz; Gary Feigenbaum; Muzammil Mushtaq; Viky Y Suncion; Albert C Lardo; Ivan Borrello; Adam Mendizabal; Tomer Z Karas; John Byrnes; Maureen Lowery; Alan W Heldman; Joshua M Hare Journal: Circ Res Date: 2014-02-24 Impact factor: 17.367
Authors: Bodo E Strauer; Michael Brehm; Tobias Zeus; Thomas Bartsch; Christina Schannwell; Christine Antke; Rüdiger V Sorg; Gesine Kögler; Peter Wernet; Hans-Wilhelm Müller; Matthias Köstering Journal: J Am Coll Cardiol Date: 2005-11-01 Impact factor: 24.094
Authors: Yi Fu Zhou; Marta Bosch-Marce; Hiroaki Okuyama; Balaji Krishnamachary; Hideo Kimura; Li Zhang; David L Huso; Gregg L Semenza Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: M B Britten; N D Abolmaali; B Assmus; R Lehmann; J Honold; J Schmitt; T J Vogl; H Martin; V Schächinger; S Dimmeler; A M Zeiher Journal: Circulation Date: 2003-10-13 Impact factor: 29.690
Authors: Jingcai Wang; Min Gong; Shi Zuo; Jie Xu; Chris Paul; Hongxia Li; Min Liu; Yi-Gang Wang; Muhammad Ashraf; Meifeng Xu Journal: Genes (Basel) Date: 2020-10-29 Impact factor: 4.096
Authors: Ria Margiana; Alexander Markov; Angelina O Zekiy; Mohammed Ubaid Hamza; Khalid A Al-Dabbagh; Sura Hasan Al-Zubaidi; Noora M Hameed; Irshad Ahmad; R Sivaraman; Hamzah H Kzar; Moaed E Al-Gazally; Yasser Fakri Mustafa; Homayoon Siahmansouri Journal: Stem Cell Res Ther Date: 2022-07-28 Impact factor: 8.079